See more : ayfie Group AS (AYFGF) Income Statement Analysis – Financial Results
Complete financial analysis of Reunion Neuroscience Inc. (REUN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Reunion Neuroscience Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Premium Nickel Resources Ltd. (PNRLF) Income Statement Analysis – Financial Results
- Beijing Tong Ren Tang Chinese Medicine Company Limited (3613.HK) Income Statement Analysis – Financial Results
- Merck & Co., Inc. (6MK.DE) Income Statement Analysis – Financial Results
- Eldav Investments Ltd. (ELDAV.TA) Income Statement Analysis – Financial Results
- Procore Technologies, Inc. (PCOR) Income Statement Analysis – Financial Results
Reunion Neuroscience Inc. (REUN)
About Reunion Neuroscience Inc.
Field Trip Health Ltd. engages in the development and delivery of psychedelic- assisted therapies in North America. The company operates Field Trip Health Centres that provide psychedelic therapies; offers Field Trip Digital apps; operates Field Trip Discovery, a drug development division that develops the next generation of psychedelic molecules; and provides ketamine-assisted therapy for the treatment of depression, anxiety, addiction, and other conditions. Field Trip Health Ltd. was founded in 2008 and is headquartered in Toronto, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|
| Revenue | 0.00 | 4.86M | 960.90K | 1.00K |
| Cost of Revenue | 0.00 | 9.15M | 1.54M | 9.40K |
| Gross Profit | 0.00 | -4.29M | -583.43K | -8.40K |
| Gross Profit Ratio | 0.00% | -88.27% | -60.72% | -840.30% |
| Research & Development | 12.98M | 7.31M | 3.42M | 193.19K |
| General & Administrative | 12.96M | 34.48M | 12.06M | 2.63M |
| Selling & Marketing | 0.00 | 3.23M | 1.63M | 305.71K |
| SG&A | 12.96M | 37.72M | 13.69M | 2.93M |
| Other Expenses | 2.02M | 3.71M | 1.34M | 139.98K |
| Operating Expenses | 27.96M | 48.74M | 18.45M | 3.27M |
| Cost & Expenses | 27.96M | 57.89M | 19.99M | 3.28M |
| Interest Income | 691.79K | 425.90K | 51.04K | 2.66K |
| Interest Expense | 17.73M | 1.10M | 303.30K | 22.56K |
| Depreciation & Amortization | 3.23M | 3.60M | 1.39M | 146.32K |
| EBITDA | -17.15M | -49.00M | -17.58M | -3.13M |
| EBITDA Ratio | 0.00% | -1,008.13% | -1,829.88% | -312,585.70% |
| Operating Income | -20.37M | -52.60M | -18.98M | -3.27M |
| Operating Income Ratio | 0.00% | -1,082.27% | -1,974.99% | -327,217.70% |
| Total Other Income/Expenses | -17.73M | 14.50M | -4.14M | 643.85K |
| Income Before Tax | -38.10M | -54.69M | -23.12M | -2.63M |
| Income Before Tax Ratio | 0.00% | -1,125.30% | -2,405.84% | -262,832.40% |
| Income Tax Expense | 28.12M | 1.10M | 303.30K | 22.56K |
| Net Income | -66.22M | -55.79M | -23.42M | -2.65M |
| Net Income Ratio | 0.00% | -1,147.86% | -2,437.41% | -265,088.60% |
| EPS | -5.69 | -4.83 | -3.54 | -0.35 |
| EPS Diluted | -5.69 | -4.83 | -3.54 | -0.35 |
| Weighted Avg Shares Out | 11.64M | 11.55M | 6.61M | 7.60M |
| Weighted Avg Shares Out (Dil) | 11.64M | 11.55M | 6.61M | 7.60M |
Reunion Neuroscience Partners with Seleni Institute on Effective Diagnosis and Treatment of Maternal Mental Health Disorders
Reunion to Sponsor Scholarships that will Train Healthcare Professionals on Maternal Mental Health Disorders, including Postpartum Depression
Reunion Neuroscience Appoints Mark Pollack, M.D., as Chief Medical Officer
MORRISTOWN, N.J., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc., a clinical-stage biopharmaceutical company committed to revolutionizing the treatment of underserved mental health disorders through the advancement of next-generation psychedelic therapeutic solutions, today announced the appointment of Mark Pollack,...
Reunion Neuroscience Joins the Is Mom OK? Initiative Recognizing Maternal Suicide Prevention Month
Initiative Coincides with Start of Reunion's Phase 2 RECONNECT Study in Postpartum Depression Initiative Coincides with Start of Reunion's Phase 2 RECONNECT Study in Postpartum Depression
Reunion Neuroscience Inc. Announces Upcoming Presentations at the Anxiety and Depression Association of America (ADAA) 2024 Conference
MORRISTOWN, N.J., April 03, 2024 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc., a venture backed clinical-stage biopharmaceutical company committed to pushing the boundaries of neuroscience, today announced that the clinical dataset from the Company's Phase 1 study of its lead asset,...
Reunion Neuroscience Inc. to Participate in October Investor Conferences
WILMINGTON, N.C., Oct. 05, 2023 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc., a venture backed clinical-stage biopharmaceutical company committed to developing innovative and patented therapeutic solutions for underserved mental health conditions, today announced that Greg Mayes, Chief Executive Officer, will participate...
Reunion Neuroscience Inc. Announces FDA Clearance of IND Application to Initiate a Phase 2 Study of RE104 for the Treatment of Postpartum Depression
WILMINGTON, Del., Sept. 18, 2023 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc., a clinical-stage biopharmaceutical company committed to developing innovative and patented therapeutic solutions for underserved mental health conditions today announced that the U.S. Food and Drug Administration (FDA) has cleared...
Reunion Neuroscience Inc. and MPM BioImpact Announce Completion of Plan of Arrangement
TORONTO, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (TSX: REUN, NASDAQ: REUN) ("Reunion" or the "Company"), a clinical-stage biopharmaceutical company committed to developing innovative and patented therapeutic solutions for underserved mental health conditions and MPM BioImpact ("MPM") are...
Reunion Neuroscience Inc. Shareholders Approve Proposed Plan of Arrangement
TORONTO, July 13, 2023 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (TSX: REUN, NASDAQ: REUN) ("Reunion" or the “Company”), a clinical-stage biopharmaceutical company committed to developing innovative and patented therapeutic solutions for underserved mental health conditions, is pleased to announce the...
Reunion Neuroscience sees $48.5M loss in FY23 ahead of going private
Reunion Neuroscience Inc Thursday reported a net loss of $48,492,996 for its fiscal year 2023, even as the company remains upbeat on the development of its psychedelic treatment for postpartum depression. Reunion, formerly known as Field Trip Health & Wellness Ltd,...
The 7 Most Promising Penny Stocks to Buy in June
Some of the most promising penny stocks are up-and-coming and just just getting started. The world of penny stocks is all about speculating which young firms have the potential to become the next big companies.
Source: https://incomestatements.info
Category: Stock Reports